Literature DB >> 12881310

The kringle stabilizes urokinase binding to the urokinase receptor.

Khalil Bdeir1, Alice Kuo, Bruce S Sachais, Ann H Rux, Yasmina Bdeir, Andrew Mazar, Abd Al-Roof Higazi, Douglas B Cines.   

Abstract

The structural basis of the interaction between single-chain urokinase-type plasminogen activator (scuPA) and its receptor (uPAR) is incompletely defined. Several observations indicated the kringle facilitates the binding of uPA to uPAR. A scuPA variant lacking the kringle (Delta K-scuPA) bound to soluble uPAR (suPAR) with the similar "on-rate" but with a faster "off-rate" than wild-type (WT)-scuPA. Binding of Delta K-scuPA, but not WT-scuPA, to suPAR was comparably inhibited by its growth factor domain (GFD) and amino-terminal fragment (ATF). ATF and WT-scuPA, but not GFD, scuPA lacking the GFD (Delta GFD-scuPA), or Delta K-scuPA reconstituted the isolated domains of uPAR. ATF completely inhibited the enzymatic activity of WT-scuPA-suPAR unlike comparable concentrations of GFD. Variants containing mutations that alter the charge, length, or flexibility of linker sequence (residues 43-49) between the GFD and the kringle displayed a lower affinity for uPAR, were unable to reconstitute uPAR domains, and their binding to uPAR was inhibited by GFD in the same manner as Delta K-scuPA. A scuPA variant in which the charged amino acids in the heparin binding site (HBS) in the kringle domain were mutated to alanines behaved like Delta K-scuPA, indicating that that the structure of the kringle as well as its interaction with the GFD govern receptor binding. These data demonstrate an important role for the kringle in stabilizing the binding of scuPA to uPAR.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12881310     DOI: 10.1182/blood-2003-03-0949

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  Fibulin-5 binds urokinase-type plasminogen activator and mediates urokinase-stimulated β1-integrin-dependent cell migration.

Authors:  Alexander Kapustin; Victoria Stepanova; Natalia Aniol; Douglas B Cines; Alexei Poliakov; Serge Yarovoi; Tatiana Lebedeva; Robin Wait; Grigory Ryzhakov; Yelena Parfyonova; Yaroslav Gursky; Hiromi Yanagisawa; Mikhail Minashkin; Robert Beabealashvilli; Alexander Vorotnikov; Alex Bobik; Vsevolod Tkachuk
Journal:  Biochem J       Date:  2012-04-15       Impact factor: 3.857

2.  Structural basis of interaction between urokinase-type plasminogen activator and its receptor.

Authors:  Cyril Barinka; Graham Parry; Jennifer Callahan; David E Shaw; Alice Kuo; Khalil Bdeir; Douglas B Cines; Andrew Mazar; Jacek Lubkowski
Journal:  J Mol Biol       Date:  2006-08-26       Impact factor: 5.469

3.  Ab initio molecular simulations for proposing novel peptide inhibitors blocking the ligand-binding pocket of urokinase receptor.

Authors:  Tatsuroh Mizushima; Takuya Sugimoto; Tomoyo Kasumi; Kohta Araki; Hiroshi Kobayashi; Noriyuki Kurita
Journal:  J Mol Model       Date:  2014-05-25       Impact factor: 1.810

4.  Number and brightness image analysis reveals ATF-induced dimerization kinetics of uPAR in the cell membrane.

Authors:  Christian Hellriegel; Valeria R Caiolfa; Valeria Corti; Nicolai Sidenius; Moreno Zamai
Journal:  FASEB J       Date:  2011-05-20       Impact factor: 5.191

5.  Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature.

Authors:  Bi-Sen Ding; Claudia Gottstein; Andrea Grunow; Alice Kuo; Kumkum Ganguly; Steven M Albelda; Douglas B Cines; Vladimir R Muzykantov
Journal:  Blood       Date:  2005-09-06       Impact factor: 22.113

6.  Urokinase-type Plasminogen Activator (uPA) Promotes Angiogenesis by Attenuating Proline-rich Homeodomain Protein (PRH) Transcription Factor Activity and De-repressing Vascular Endothelial Growth Factor (VEGF) Receptor Expression.

Authors:  Victoria Stepanova; Padma-Sheela Jayaraman; Sergei V Zaitsev; Tatiana Lebedeva; Khalil Bdeir; Rachael Kershaw; Kelci R Holman; Yelena V Parfyonova; Ekaterina V Semina; Irina B Beloglazova; Vsevolod A Tkachuk; Douglas B Cines
Journal:  J Biol Chem       Date:  2016-05-04       Impact factor: 5.157

Review 7.  Advanced drug delivery systems for antithrombotic agents.

Authors:  Colin F Greineder; Melissa D Howard; Ronald Carnemolla; Douglas B Cines; Vladimir R Muzykantov
Journal:  Blood       Date:  2013-06-24       Impact factor: 22.113

8.  Interaction of high-molecular-weight kininogen with endothelial cell binding proteins suPAR, gC1qR and cytokeratin 1 determined by surface plasmon resonance (BiaCore).

Authors:  R A Pixley; R G Espinola; B Ghebrehiwet; K Joseph; A Kao; K Bdeir; D B Cines; R W Colman
Journal:  Thromb Haemost       Date:  2011-05-05       Impact factor: 5.249

9.  Soluble urokinase receptor conjugated to carrier red blood cells binds latent pro-urokinase and alters its functional profile.

Authors:  Juan-Carlos Murciano; Abd Al-Roof Higazi; Douglas B Cines; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2009-07-16       Impact factor: 9.776

10.  Nuclear translocation of urokinase-type plasminogen activator.

Authors:  Victoria Stepanova; Tatiana Lebedeva; Alice Kuo; Serge Yarovoi; Sergei Tkachuk; Sergei Zaitsev; Khalil Bdeir; Inna Dumler; Michael S Marks; Yelena Parfyonova; Vsevolod A Tkachuk; Abd Al-Roof Higazi; Douglas B Cines
Journal:  Blood       Date:  2008-03-12       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.